In the news

Jenny Dandin is an R&D engineer at Boston Scientific. In a recent telephone interview with Career Communications Group, she shared a unique perspective from her experience as a female making her way as an engineer at a top medical device company.

Paudie O’Connor, senior vice president of supply chain, shares lessons learned from the last few years of macro supply chain challenges, and why Boston Scientific puts its people at the center.

Medical technology company Boston Scientific is among the organizations working to reverse the under-representation of women and people of color specifically Black patients, in clinical trials. Its aptly named Close the Gap program aims to level the medical playing field.

Boston Scientific Corp. scaled back some shifts at its facilities in Puerto Rico in light of travel advisories, a spokeswoman said. But its sites remain fully functional and the company expects operations to resume at normal levels once the storm subsides and travel advisories are lifted.

Brad Sorenson, executive vice president, Global Operations, and Paudie O’Connor, senior vice president of supply chain, discuss how supply chain has evolved in recent years, including strategic supplier relationships, resilience and continuity planning and sustainability.

Boston Scientific has been named one of Fast Company's Best Workplaces for Innovators for the third consecutive year—this year earning a callout as a best workplace for women.

Gail Beauregard, vice president of global total rewards at Boston Scientific, discusses how the company strives to create an organization where employees feel that they belong and can do their best work.

Camille Chang Gilmore, vice president, human resources and global chief diversity, equity and inclusion officer at Boston Scientific shares how the company’s diversity and inclusion efforts are promoting equity with its caring culture.

How has Boston Scientific evolved over the last decade? What is the difference between a leader and a manager? What does it mean to prioritize innovation? Charmain and CEO Mike Mahoney answers these questions and more during a sit down with DeviceTalks.

Boston Scientific’s WATCHMAN FLX™ is associated with fewer major adverse events and higher rates of success than its predecessor, according to an analysis of registry data by researchers at Yale School of Medicine. The study looked at 27,000 recipients of Boston Scientific’s first-generation WATCHMAN 2.5, and the same number of recipients of its successor WATCHMAN FLX. The rate of major in-hospital adverse events was 1.35% in the FLX arm and 2.4% in the Watchman 2.5 cohort.